<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079104</url>
  </required_header>
  <id_info>
    <org_study_id>CS002</org_study_id>
    <nct_id>NCT01079104</nct_id>
  </id_info>
  <brief_title>Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units</brief_title>
  <acronym>HEPATICUS-2</acronym>
  <official_title>Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepa Wash GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepa Wash GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hepatic dysfunction are known to have a high mortality rate. Hepa Wash(R) is a
      newly developed liver and renal support system that is based on the use of recycled albumin
      dialysate. The new system has shown a high detoxification capacity in in-vitro and
      preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa
      Wash system in patients with hepatic dysfunction in the intensive care unit.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The foundations of our pilotstudy planning has changed.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day mortality rate</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiorgan system failure</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (surrogate parameters)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without extracorporeal treatment</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180d-mortality rate</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1y-mortality rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Liver Dysfunction</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Medical Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepa Wash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the liver support system &quot;Hepa Wash&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hepa Wash</intervention_name>
    <description>Intervention frequency: 1-10 treatments (decision of the investigator)
Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)</description>
    <arm_group_label>Hepa Wash</arm_group_label>
    <other_name>Hepa Wash procedure</other_name>
    <other_name>the HIP1001 system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Medical Therapy</intervention_name>
    <description>Standard of care treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Bilirubin ≥ 2 mg/dl AND

          2. SOFA-score ≥ 9 calculated 12 hours after initiating medical resuscitation measures AND

          3. Patient is in the intensive care unit AND

          4. Signed informed consent of the patient or legal representative AND

          5. Patients are 18 years or older AND

          6. Enrollment of patients within 96 hours of fulfilling inclusion criteria (1-3).

        Exclusion Criteria:

          1. Patient with known history of chronic liver disease

          2. Untreatable extrahepatic cholestasis

          3. Patient has a survival prognosis of less than 6 weeks because of a chronic disease
             (e.g. metastasizing cancer) and before the acute event which lead to the ICU
             admission.

          4. PaO2/FIO2 ≤ 100 mmHg

          5. Patients on kidney dialysis

          6. Patients with MELD-score of 40

          7. Mean arterial pressure ≤ 50 mmHg despite conventional medical treatment

          8. Patient testament excludes the use of life-prolonging measures

          9. Post-operative patients whose liver failure is related to liver surgery

         10. Uncontrolled seizures

         11. Active or uncontrolled bleeding

         12. Weight ≥ 120 kg

         13. Pregnancy

         14. Patient diagnosed with Creutzfeldt-Jakob disease

         15. Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Huber, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>II Medizinische Klinik, Klinikum rechts der Isar, Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>II Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver failure</keyword>
  <keyword>Hepatic insufficiency</keyword>
  <keyword>Artificial liver</keyword>
  <keyword>Albumin dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

